Neuroprotective effects of a systemically active group II metabotropic glutamate receptor agonist LY354740 in a gerbil model of global ischaemia.
The neuroprotective effects of a novel Group II metabotropic glutamate receptor (mGluR) agonist, LY354740, have been evaluated in a gerbil model of global ischaemia. When administered at 50 mg/kg, i.p., 30 min and 6 h after a 3 min period of bilateral carotid artery occlusion (BCAO), the compound reduced the damage to CA1 hippocampal neurones to a significant level. However, when the ischaemic insult was made more severe, by increasing the period of occlusion to 4 and 5 min, the neuroprotective effects of LY354740 were reduced. From these findings, it would appear that Group II mGluRs may play a role in ischaemic damage in the gerbil hippocampus and that agonists at these receptors are potential neuroprotective agents.
Bond
A
A
Lilly Research Centre, Eli Lilly & Co, Windlesham, Surrey, UK.
O'Neill
M J
MJ
Hicks
C A
CA
Monn
J A
JA
Lodge
D
D
D000818:Animals; D002545:Brain Ischemia / Q000188:drug therapy*; D001643:Bridged Bicyclo Compounds / Q000494:pharmacology*; D004195:Disease Models, Animal; D018690:Excitatory Amino Acid Agonists / Q000494:pharmacology*; D005849:Gerbillinae; D008297:Male; D018696:Neuroprotective Agents / Q000494:pharmacology*; D018094:Receptors, Metabotropic Glutamate / Q000819:agonists*
D001643:Bridged Bicyclo Compounds; D018690:Excitatory Amino Acid Agonists; D018696:Neuroprotective Agents; D018094:Receptors, Metabotropic Glutamate; C104753:eglumetad